- Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to conditions with unmet needs
- The subject of an ongoing Phase I clinical trial, Odyssey’s PRV-002 is a novel compound for treating concussion, which currently has no FDA-approved drug
- Data from Cohort I of the Phase I study showed that PRV-002 is well-tolerated, with no adverse events being observed
- The company believes that, if PRV-002 is found to be efficacious for concussed patients in the Phase 2/3 trials, the intranasal brain-targeting will be the key to its success
- Phase 1 and 2 drugs represent valuable assets, with large companies entering into multimillion and even multibillion-dollar agreements to license drug candidates while they are still undergoing clinical trials
Between 3 and 5 million concussions happen every year in the US alone, though only 1 in 2 cases are reported or detected (https://ibn.fm/lE7Nv). Also known as mild traumatic brain injury (“mTBI”), a concussion is caused by a jolt, blow or bump to the head, or a hit to the body that causes the head to shift positions quickly causing the brain to stretch.
In describing concussion as a complicated injury, a recent Washington Post article notes: “Every concussion is unique, so symptoms and recovery times vary between individuals, even if they were hit with the same force on the same part of their…
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.